Clinical and Experimental Nephrology

, Volume 11, Issue 2, pp 107–114

Pathogenesis and prognosis of thrombotic microangiopathy

Authors

    • Division of Nephrology and EndocrinologyUniversity of Tokyo School of Medicine
  • Hiroshi Nishi
    • Division of Nephrology and EndocrinologyUniversity of Tokyo School of Medicine
  • Toshiro Fujita
    • Division of Nephrology and EndocrinologyUniversity of Tokyo School of Medicine
REVIEW ARTICLE

DOI: 10.1007/s10157-007-0466-7

Cite this article as:
Nangaku, M., Nishi, H. & Fujita, T. Clin Exp Nephrol (2007) 11: 107. doi:10.1007/s10157-007-0466-7

Abstract

Thrombotic microangiopathy (TMA) is a clinicopathological syndrome characterized by thrombosis formation in the microvasculature of various organs. Included in the broad category of TMA are the hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Typical HUS is caused by Escherichia coli O157:H7, which produces the Shiga-like toxins; Stx-1 and Stx-2. In addition to damaging endothelial cells via the inhibition of protein synthesis, Shiga-like toxins also activate endothelial cells to produce inflammatory mediators, amplifying the prothrombogenic state. Although most patients with typical HUS recover renal functions, recent analysis has shown that typical HUS is not a benign disease in the long term. Genetic abnormalities of complement regulatory proteins predispose patients to atypical HUS. Mutations in factor H, membrane cofactor protein, and factor I are known to be associated with atypical HUS. Atypical HUS forms have a poor outcome and show recurrent and progressive courses. Autoimmune IgG inhibitors of a disintegrin and metalloprotease, with thrombospodin-1-like domains (ADAMTS) 13 and mutations of the ADAMTS13 gene lead to the development of TTP. Without treatment, TTP is associated with a very high mortality rate. As it is for atypical HUS, plasma exchange is currently the most feasible treatment for TTP. Etiological diagnosis at the bedside and the development of disease-specific therapeutic modalities will enable us to optimize the management of patients with TMA and improve their prognosis in the future.

Key words

Thrombotic microangiopathy (TMA)Hemolytic uremic syndrome (HUS)Thrombotic thrombocytopenic purpura (TTP)
Download to read the full article text

Copyright information

© Japanese Society of Nephrology 2007